- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02100865
Solar Powered Oxygen Delivery
Solar Powered Oxygen Delivery: An Open-label Non-inferiority Comparison to Standard Oxygen Delivery Using Oxygen Cylinders
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Arterial hypoxemia in pneumonia results from several mechanisms: pulmonary arterial blood flow to consolidated lung resulting in an intrapulmonary shunt, intrapulmonary oxygen consumption, and ventilation-perfusion mismatch. Hypoxemia is a risk factor for mortality in pediatric pneumonia, and was associated with a 5-fold increased risk of death in studies from Kenya and Gambia.
In one report from Nepal, the prevalence of hypoxemia (SpO2 < 90%) in 150 children with pneumonia was 39% overall, with increasing rates of hypoxemia across strata of pneumonia severity (100% of very severe, 80% of severe and 17% of pneumonia patients). General features of respiratory distress were associated with hypoxemia in this study, including chest indrawing, lethargy, grunting, nasal flaring, cyanosis, inability to breastfeed or drink.
Few studies have reported on the use of solar powered oxygen (SPO2) delivery. One online report describes the use of a battery-powered oxygenator in the Gambia that could be adapted to use solar power (http://www.dulas.org.uk). Otherwise, our intervention is to our knowledge the first example of SPO2 delivery.
New ways to deliver oxygen for children with pneumonia in Africa could improve outcomes and save numerous lives. If this study documents the non-inferiority of SPO2 relative to standard oxygen delivery, this novel method of providing life-saving oxygen could be rolled out across centres in sub-Saharan Africa where oxygen cylinders are not widely available and electrical power is not reliable. The potential energy efficiency, low cost and ease of use make solar power an attractive avenue of investigation for use in resource-constrained settings. Proof-of-concept that the sun can be used to drive oxygen delivery could stimulate commercial interest in this technology. The SPO2 system could thus achieve rapid penetration into the most remote or rural settings in sub-Saharan Africa.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Jinja, Uganda
- Jinja Regional Referral Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age <13 years
- IMCI defined pneumonia, severe pneumonia or very severe disease
- Hypoxemia (SpO2<90%) based on non-invasive pulse oximetry
- Hospital admission warranted based on clinician judgment
- Consent to blood sampling and data collection
Exclusion Criteria:
- SpO2 ≥90%
- Suspected pulmonary tuberculosis
- Outpatient management
- Denial of consent to participate in study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Solar powered oxygen
Solar panels used to drive an oxygen concentrator to deliver at stream of oxygen at approximately 90% FiO2 and a rate of 1-5L/min.
|
|
Aktiv komparator: Oxygen from cylinders
Conventional oxygen delivery from compressed gas cylinders
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Length of hospital stay
Tidsramme: Until end of hospitalization (usually 3 to 7 days)
|
The number of days from admission to discharge.
Criteria for discharge are standardized and are assessed daily.
|
Until end of hospitalization (usually 3 to 7 days)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Mortality
Tidsramme: At hospital discharge (usually 3 to 7 days)
|
In-hospital mortality will be quantified.
|
At hospital discharge (usually 3 to 7 days)
|
Duration of supplemental oxygen therapy
Tidsramme: Until hospital discharge (usually 3 to 7 days)
|
Time to wean patient off oxygen.
This is assessed daily using standard procedures.
|
Until hospital discharge (usually 3 to 7 days)
|
Proportion of patients successfully oxygenated
Tidsramme: 6 hours
|
Success defined as achieving a post-oxygen saturation above 90% within 6 hours.
|
6 hours
|
Oxygen delivery system failure
Tidsramme: During hospitalization (usually 3 to 7 days)
|
Failure defined as need for backup oxygen to maintain SpO2>90%.
|
During hospitalization (usually 3 to 7 days)
|
Cost
Tidsramme: Until hospital discharge (usually 3 to 7 days)
|
Cost of oxygen cylinders (control arm) and cost of equipment (capital investment - solar oxygen intervention arm).
|
Until hospital discharge (usually 3 to 7 days)
|
Lambaréné Organ Dysfunction Score (LODS)
Tidsramme: Until hospital discharge (usually 3 to 7 days)
|
This simple published clinical score predicts mortality in children with malaria, but may also have prognostic value in pneumonia.
|
Until hospital discharge (usually 3 to 7 days)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Michael T Hawkes, MD, PhD, University of Alberta
- Hovedetterforsker: Robert O Opoka, MBChB, MPH, Makerere University
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Duke T, Wandi F, Jonathan M, Matai S, Kaupa M, Saavu M, Subhi R, Peel D. Improved oxygen systems for childhood pneumonia: a multihospital effectiveness study in Papua New Guinea. Lancet. 2008 Oct 11;372(9646):1328-33. doi: 10.1016/S0140-6736(08)61164-2. Epub 2008 Aug 15.
- Hawkes MT, Conroy AL, Namasopo S, Bhargava R, Kain KC, Mian Q, Opoka RO. Solar-Powered Oxygen Delivery in Low-Resource Settings: A Randomized Clinical Noninferiority Trial. JAMA Pediatr. 2018 Jul 1;172(7):694-696. doi: 10.1001/jamapediatrics.2018.0228.
- Nyende S, Conroy A, Opoka RO, Namasopo S, Kain KC, Mpimbaza A, Bhargava R, Hawkes M. Solar-powered oxygen delivery: study protocol for a randomized controlled trial. Trials. 2015 Jul 9;16:297. doi: 10.1186/s13063-015-0814-y.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 0206-01
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Lungebetennelse
-
University of KentuckyPfizerFullførtMeticillin-resistent Staphylococcal Aureus PneumoniForente stater
-
Assistance Publique - Hôpitaux de ParisFullførtAlvorlige infeksjoner Pneumoni med invasiv ventilasjon i PICUFrankrike
-
Bandim Health ProjectMedical Research Council Unit, The GambiaFullført
-
Asan Medical CenterFullførtIkke-HIV-pasienter med Pneumocystis Jiroveci PneumoniKorea, Republikken
-
M.D. Anderson Cancer CenterFullførtKreft | Akutt leukemi | Respiratoriske syncytiale virusinfeksjoner | Beinmargstransplantasjonsinfeksjon | Infeksjon hos margtransplantasjonsmottakere | Respiratorisk Syncytial Virus PneumoniForente stater
Kliniske studier på Solar powered oxygen
-
Barron Associates, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development... og andre samarbeidspartnereFullført
-
AbiliTech Medical Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development... og andre samarbeidspartnereFullført
-
Ethicon Endo-SurgeryFullført
-
Yale UniversityFullførtFibroserende alopecia | Frontal fibroserende alopecia | Sentral sentrifugal cicatricial alopeciaForente stater
-
Centers for Disease Control and PreventionUniversity of Miami; Nova Southeastern University; DePaul UniversityFullførtHIV-infeksjonerForente stater
-
Yale UniversityFullførtAlopecia areataForente stater
-
University of California, Los AngelesAvsluttetHypotyreoseForente stater
-
Affiliated Cancer Hospital & Institute of Guangzhou...Guangdong Provincial People's Hospital; Zhujiang Hospital; Union hospital...Har ikke rekruttert ennåTisleilizumab (PD-1 antistoff) og kjemoradioterapi ved lokoregionalt avansert nasofaryngeal karsinomNasofaryngeale neoplasmerKina
-
Soroka University Medical CenterUkjent
-
Shirley Ryan AbilityLabNorthwestern University; Northwestern Memorial HospitalRekruttering